Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Ultrasensitive Biopsy Technique Monitors Risk of Cancer Recurrence

By LabMedica International staff writers
Posted on 19 Aug 2019
An ultrasensitive liquid biopsy technique, which may be personalized for each breast cancer patient, can be used to monitor the patient over time and allow early detection of tumor recurrence.

Analysis of tumor DNA shed into a patient’s circulation can provide a noninvasive means for detecting the presence of a tumor and analyzing its DNA for targetable mutations. More...
However, it is difficult to detect small amounts of tumor DNA in the blood, especially in patients who have already undergone initial chemotherapy treatment.

To improve the sensitivity of the liquid biopsy approach to detect minute quantities of residual tumor DNA in plasma, investigators at The Translational Genomics Research Institute (Phoenix, AZ, USA) and collaborators in the United States and the United Kingdom developed a method called “targeted digital sequencing” (TARDIS) for multiplexed analysis of patient-specific cancer mutations.

According to the investigators, TARDIS combines the strengths of PCR-based methods (minimizing losses of template DNA molecules) and ligation-based methods (incorporation of unique molecular identifiers (UMIs), preservation of fragment sizes, and hundred-fold multiplexing). This combination achieves a balance between depth and breadth of tumor genome analyzed, investigating dozens to hundreds of patient-specific mutations with deep coverage. The TARDIS method was streamlined and automated to successfully target 55% of putative founder mutations per patient on average. The technique relies on routine primer synthesis with standard purification and requires a limited sequencing footprint, making this approach cost-effective and enabling frequent and longitudinal analysis of plasma samples.

The TARDIS assay analyzes an amount of DNA equivalent to a single tube of blood and can simultaneously address eight to 16 known mutations. In the current study, TARDIS achieved up to 100-fold improvement beyond the current limit of ctDNA detection using clinically relevant blood volumes, TARDIS successfully detected ctDNA in plasma samples from 33 patients with breast cancer before they began treatment, and revealed that the patients had lower concentrations of ctDNA after treatment was completed. Furthermore, patients who responded the best to chemotherapy displayed a 96% decrease in ctDNA abundance, while patients with residual disease showed a 77% decrease - indicating the platform could guide the personalized management of patients at risk of cancer recurrence.

"By precisely measuring ctDNA, this test can detect the presence of residual cancer, and inform physicians if cancer has been successfully eradicated by treatment," said senior author Dr. Muhammed Murtaza, co-director for noninvasive diagnostics at The Translational Genomics Research Institute. "The results of these tests could be used to individualize cancer therapy avoiding overtreatment in some cases and under treatment in others. The central premise of our research is whether we can develop a blood test that can tell patients who have been completely cured apart from patients who have residual disease. We wondered whether we can see clearance of ctDNA from blood in patients who respond well to pre-surgical treatment."

The TARDIS method was described in the August 7, 2019, online edition of the journal Science Translational Medicine.

Related Links:
Translational Genomics Research Institute


New
Gold Member
Collection and Transport System
PurSafe Plus®
Collection and Transport System
PurSafe Plus®
Human Estradiol Assay
Human Estradiol CLIA Kit
New
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LungCanSeek demonstrated an overall sensitivity of 83.5% and specificity of 90.3% in detecting lung cancer (Photo courtesy of AdobeStock)

New Blood Test Offers Affordable and Accurate Early Detection of Lung Cancer

Lung cancer remains the leading cause of cancer-related deaths worldwide, largely because most cases are diagnosed at advanced stages when treatment options are limited. Early detection significantly improves... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The TriVerity IVD test includes the TriVerity cartridge and the Myrna instrument (Photo courtesy of Inflammatix)

Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients

When a patient enters the emergency department in critical condition, clinicians must rapidly decide whether the patient has an infection, whether it is bacterial or viral, and whether immediate treatment... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.